
- /
- Supported exchanges
- / US
- / IMMX.NASDAQ
Immix Biopharma Inc (IMMX NASDAQ) stock market data APIs
Immix Biopharma Inc Financial Data Overview
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Immix Biopharma Inc data using free add-ons & libraries
Get Immix Biopharma Inc Fundamental Data
Immix Biopharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -21 699 388
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.23
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immix Biopharma Inc News

ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis
LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biotech company with a market capitalization of $75.5 million, announced Friday that its sterically-optimized CAR-T cell therapy NXC...


Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory A...

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2...

Immix Biopharma Attends FDA CEO Forum in Washington DC
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.